Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
Gilead's $1,000 Pill Could Eradicate Hepatitis C, But Ethical And Financial Challenges Loom
Two-drug combo pill against hepatitis C is so effective, Wall Street analysts say, that it's possible that public health officials could begin thinking about eradicating the liver-damaging virus, which may afflict 3.2 million Americans and is spread mostly through sharing needles and needle stick injuries, according to the Centers for Disease Control & Prevention.
read more at:
http://www.forbes.com/sites/matthewherper/2013/12/19/can-gileads-1000-pill-eradicate-hepatitis-c/
Two-drug combo pill against hepatitis C is so effective, Wall Street analysts say, that it's possible that public health officials could begin thinking about eradicating the liver-damaging virus, which may afflict 3.2 million Americans and is spread mostly through sharing needles and needle stick injuries, according to the Centers for Disease Control & Prevention.
read more at:
http://www.forbes.com/sites/matthewherper/2013/12/19/can-gileads-1000-pill-eradicate-hepatitis-c/
Fight for cheap drugs shifts from AIDS to new hepatitis pills
LONDON -- A new battle is looming over access to antiviral medicines in developing countries -- this time for treating hepatitis C -- more than a decade after a global showdown over the price of AIDS drugs in Africa.
Modern pills being launched in western markets could cure the liver-destroying infection in tens of millions of people from China to Congo, or even eradicate the disease entirely. But that will only happen if the cost falls dramatically.
Drug makers like Gilead Sciences, whose product Sovaldi won US approval this month with a $1,000 a day price tag, are under mounting pressure to strike deals to avoid a rerun of the disputes that stalled early access to HIV therapy.